Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 324

1.

Comparison of molecular profile in triple-negative inflammatory and non-inflammatory breast cancer not of mesenchymal stem-like subtype.

Funakoshi Y, Wang Y, Semba T, Masuda H, Hout D, Ueno NT, Wang X.

PLoS One. 2019 Sep 18;14(9):e0222336. doi: 10.1371/journal.pone.0222336. eCollection 2019.

2.

Bone Metastasis of Breast Cancer.

Tahara RK, Brewer TM, Theriault RL, Ueno NT.

Adv Exp Med Biol. 2019;1152:105-129. doi: 10.1007/978-3-030-20301-6_7. Review.

PMID:
31456182
3.

Association between circulating tumor cells and peripheral blood monocytes in metastatic breast cancer.

De Giorgi U, Mego M, Scarpi E, Giordano A, Giuliano M, Valero V, Alvarez RH, Ueno NT, Cristofanilli M, Reuben JM.

Ther Adv Med Oncol. 2019 Aug 14;11:1758835919866065. doi: 10.1177/1758835919866065. eCollection 2019.

4.

Patient reported outcomes can improve performance status assessment: a pilot study.

Broderick JE, May M, Schwartz JE, Li M, Mejia A, Nocera L, Kolatkar A, Ueno NT, Yennu S, Lee JSH, Hanlon SE, Cozzens Philips FA, Shahabi C, Kuhn P, Nieva J.

J Patient Rep Outcomes. 2019 Jul 16;3(1):41. doi: 10.1186/s41687-019-0136-z.

5.

Perspectives on Inflammatory Breast Cancer (IBC) Research, Clinical Management and Community Engagement from the Duke IBC Consortium.

Devi GR, Hough H, Barrett N, Cristofanilli M, Overmoyer B, Spector N, Ueno NT, Woodward W, Kirkpatrick J, Vincent B, Williams KP, Finley C, Duff B, Worthy V, McCall S, Hollister BA, Palmer G, Force J, Westbrook K, Fayanju O, Suneja G, Dent SF, Hwang ES, Patierno SR, Marcom PK.

J Cancer. 2019 Jun 4;10(15):3344-3351. doi: 10.7150/jca.31176. eCollection 2019. Review.

6.

The impact of Ki-67 in the context of multidisciplinary care in primary inflammatory breast cancer.

Ning J, Fouad TM, Lin H, Sahin AA, Lucci A, Woodward WA, Krishnamurthy S, Tripathy D, Ueno NT, Shen Y.

J Cancer. 2019 Jun 2;10(12):2635-2642. doi: 10.7150/jca.32453. eCollection 2019.

7.

Excellent Locoregional Control in Inflammatory Breast Cancer With a Personalized Radiation Therapy Approach.

Stecklein SR, Rosso KJ, Nuanjing J, Tadros AB, Weiss A, DeSnyder SM, Kuerer HM, Teshome M, Buchholz TA, Stauder MC, Ueno NT, Lucci A, Woodward WA.

Pract Radiat Oncol. 2019 May 24. pii: S1879-8500(19)30142-0. doi: 10.1016/j.prro.2019.05.011. [Epub ahead of print]

PMID:
31132433
8.

A phase Ib study of entinostat plus lapatinib with or without trastuzumab in patients with HER2-positive metastatic breast cancer that progressed during trastuzumab treatment.

Lim B, Murthy RK, Lee J, Jackson SA, Iwase T, Davis DW, Willey JS, Wu J, Shen Y, Tripathy D, Alvarez R, Ibrahim NK, Brewster AM, Barcenas CH, Brown PH, Giordano SH, Moulder SL, Booser DJ, Moscow JA, Piekarz R, Valero V, Ueno NT.

Br J Cancer. 2019 Jun;120(12):1105-1112. doi: 10.1038/s41416-019-0473-y. Epub 2019 May 17.

PMID:
31097774
9.

Elevated serum levels of sialyl Lewis X (sLeX) and inflammatory mediators in patients with breast cancer.

Cohen EN, Fouad TM, Lee BN, Arun BK, Liu D, Tin S, Gutierrez Barrera AM, Miura T, Kiyokawa I, Yamashita J, Alvarez RH, Valero V, Woodward WA, Shen Y, Ueno NT, Cristofanilli M, Reuben JM.

Breast Cancer Res Treat. 2019 Aug;176(3):545-556. doi: 10.1007/s10549-019-05258-0. Epub 2019 May 3.

PMID:
31054033
10.

Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer.

Reddy SM, Reuben A, Barua S, Jiang H, Zhang S, Wang L, Gopalakrishnan V, Hudgens CW, Tetzlaff MT, Reuben JM, Tsujikawa T, Coussens LM, Wani K, He Y, Villareal L, Wood A, Rao A, Woodward WA, Ueno NT, Krishnamurthy S, Wargo JA, Mittendorf EA.

Cancer Immunol Res. 2019 Jun;7(6):1025-1035. doi: 10.1158/2326-6066.CIR-18-0619. Epub 2019 May 1.

PMID:
31043414
11.

Imaging features of triple-negative breast cancers according to androgen receptor status.

Candelaria RP, Adrada BE, Wei W, Thompson AM, Santiago L, Lane DL, Huang ML, Arribas EM, Rauch GM, Symmans WF, Gilcrease MZ, Huo L, Lim B, Ueno NT, Moulder SL, Yang WT.

Eur J Radiol. 2019 May;114:167-174. doi: 10.1016/j.ejrad.2019.03.017. Epub 2019 Mar 21.

PMID:
31005169
12.

Correction to: Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.

Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT.

Breast Cancer Res Treat. 2019 Jul;176(1):251. doi: 10.1007/s10549-019-05218-8.

PMID:
30982934
13.

Prediction of Bone Metastasis in Inflammatory Breast Cancer Using a Markov Chain Model.

Fujii T, Mason J, Chen A, Kuhn P, Woodward WA, Tripathy D, Newton PK, Ueno NT.

Oncologist. 2019 Apr 5. pii: theoncologist.2018-0713. doi: 10.1634/theoncologist.2018-0713. [Epub ahead of print]

PMID:
30952823
14.

Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer.

Lee J, Lim B, Pearson T, Choi K, Fuson JA, Bartholomeusz C, Paradiso LJ, Myers T, Tripathy D, Ueno NT.

Breast Cancer Res Treat. 2019 Jun;175(2):339-351. doi: 10.1007/s10549-019-05166-3. Epub 2019 Mar 2. Erratum in: Breast Cancer Res Treat. 2019 Apr 15;:.

PMID:
30826934
15.

Author Correction: Landscape of somatic mutations in 560 breast cancer whole-genome sequences.

Nik-Zainal S, Davies H, Staaf J, Ramakrishna M, Glodzik D, Zou X, Martincorena I, Alexandrov LB, Martin S, Wedge DC, Van Loo P, Ju YS, Smid M, Brinkman AB, Morganella S, Aure MR, Lingjærde OC, Langerød A, Ringnér M, Ahn SM, Boyault S, Brock JE, Broeks A, Butler A, Desmedt C, Dirix L, Dronov S, Fatima A, Foekens JA, Gerstung M, Hooijer GKJ, Jang SJ, Jones DR, Kim HY, King TA, Krishnamurthy S, Lee HJ, Lee JY, Li Y, McLaren S, Menzies A, Mustonen V, O'Meara S, Pauporté I, Pivot X, Purdie CA, Raine K, Ramakrishnan K, Rodríguez-González FG, Romieu G, Sieuwerts AM, Simpson PT, Shepherd R, Stebbings L, Stefansson OA, Teague J, Tommasi S, Treilleux I, Van den Eynden GG, Vermeulen P, Vincent-Salomon A, Yates L, Caldas C, Van't Veer L, Tutt A, Knappskog S, Tan BKT, Jonkers J, Borg Å, Ueno NT, Sotiriou C, Viari A, Futreal PA, Campbell PJ, Span PN, Van Laere S, Lakhani SR, Eyfjord JE, Thompson AM, Birney E, Stunnenberg HG, van de Vijver MJ, Martens JWM, Børresen-Dale AL, Richardson AL, Kong G, Thomas G, Stratton MR.

Nature. 2019 Feb;566(7742):E1. doi: 10.1038/s41586-019-0883-2.

PMID:
30659290
16.

Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study.

Yam C, Esteva FJ, Patel MM, Raghavendra AS, Ueno NT, Moulder SL, Hess KR, Shroff GS, Hodge S, Koenig KH, Chavez Mac Gregor M, Griner RL, Yeung SJ, Hortobagyi GN, Valero V.

Invest New Drugs. 2019 Apr;37(2):345-351. doi: 10.1007/s10637-018-0700-z. Epub 2019 Jan 5.

PMID:
30610588
17.

Cooperative Effect of Oncogenic MET and PIK3CA in an HGF-Dominant Environment in Breast Cancer.

Liu S, Li S, Wang B, Liu W, Gagea M, Chen H, Sohn J, Parinyanitikul N, Primeau T, Do KA, Vande Woude GF, Mendelsohn J, Ueno NT, Mills GB, Tripathy D, Gonzalez-Angulo AM.

Mol Cancer Ther. 2019 Feb;18(2):399-412. doi: 10.1158/1535-7163.MCT-18-0710. Epub 2018 Dec 5.

PMID:
30518672
18.

Eicosapentaenoic acid in combination with EPHA2 inhibition shows efficacy in preclinical models of triple-negative breast cancer by disrupting cellular cholesterol efflux.

Torres-Adorno AM, Vitrac H, Qi Y, Tan L, Levental KR, Fan YY, Yang P, Chapkin RS, Eckhardt BL, Ueno NT.

Oncogene. 2019 Mar;38(12):2135-2150. doi: 10.1038/s41388-018-0569-5. Epub 2018 Nov 20.

19.

Rates of immune cell infiltration in patients with triple-negative breast cancer by molecular subtype.

Harano K, Wang Y, Lim B, Seitz RS, Morris SW, Bailey DB, Hout DR, Skelton RL, Ring BZ, Masuda H, Rao AUK, Laere SV, Bertucci F, Woodward WA, Reuben JM, Krishnamurthy S, Ueno NT.

PLoS One. 2018 Oct 12;13(10):e0204513. doi: 10.1371/journal.pone.0204513. eCollection 2018.

20.

Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis.

Kono M, Fujii T, Matsuda N, Harano K, Chen H, Wathoo C, Joon AY, Tripathy D, Meric-Bernstam F, Ueno NT.

J Cancer. 2018 Sep 8;9(19):3640-3646. doi: 10.7150/jca.26825. eCollection 2018.

21.

Distinct epidemiological profiles associated with inflammatory breast cancer (IBC): A comprehensive analysis of the IBC registry at The University of Texas MD Anderson Cancer Center.

Fouad TM, Ueno NT, Yu RK, Ensor JE, Alvarez RH, Krishnamurthy S, Lucci A, Reuben JM, Yang W, Willey JS, Valero V, Bondy ML, Cristofinalli M, Shete S, Woodward WA, El-Zein R.

PLoS One. 2018 Sep 24;13(9):e0204372. doi: 10.1371/journal.pone.0204372. eCollection 2018.

22.

Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis.

Shen Y, Fujii T, Ueno NT, Tripathy D, Fu N, Zhou H, Ning J, Xiao L.

Breast Cancer Res Treat. 2019 Jan;173(1):1-9. doi: 10.1007/s10549-018-4969-6. Epub 2018 Sep 21.

PMID:
30242579
23.

ST8SIA1 Regulates Tumor Growth and Metastasis in TNBC by Activating the FAK-AKT-mTOR Signaling Pathway.

Nguyen K, Yan Y, Yuan B, Dasgupta A, Sun J, Mu H, Do KA, Ueno NT, Andreeff M, Battula VL.

Mol Cancer Ther. 2018 Dec;17(12):2689-2701. doi: 10.1158/1535-7163.MCT-18-0399. Epub 2018 Sep 20.

PMID:
30237308
24.

Preclinical and phase I clinical studies of KW-2450, a dual IGF-1R/IR tyrosine kinase inhibitor, in combination with lapatinib and letrozole.

Umehara H, Maekawa Y, Koizumi F, Shimizu M, Ota T, Fouad TM, Willey J, Kaito H, Shiraishi N, Nakashima D, Akinaga S, Ueno NT.

Ther Adv Med Oncol. 2018 Jul 30;10:1758835918786858. doi: 10.1177/1758835918786858. eCollection 2018.

25.

Neoadjuvant Pertuzumab-containing Regimens Improve Pathologic Complete Response Rates in Stage II to III HER-2/neu-positive Breast Cancer: A Retrospective, Single Institution Experience.

Murthy RK, Raghavendra AS, Hess KR, Fujii T, Lim B, Barcenas CH, Zhang H, Chavez-Mac-Gregor M, Mittendorf EA, Litton JK, Giordano SH, Thompson AM, Valero V, Moulder SL, Tripathy D, Ueno NT.

Clin Breast Cancer. 2018 Dec;18(6):e1283-e1288. doi: 10.1016/j.clbc.2018.07.008. Epub 2018 Jul 10.

PMID:
30077429
26.

Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer.

Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, Kim TB, Mendelsohn J, Mills Shaw KR, Tripathy D, Mills GB, Chen K.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00245. Epub 2018 Apr 25.

27.

Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer.

Menta A, Fouad TM, Lucci A, Le-Petross H, Stauder MC, Woodward WA, Ueno NT, Lim B.

Surg Clin North Am. 2018 Aug;98(4):787-800. doi: 10.1016/j.suc.2018.03.009. Epub 2018 May 24. Review.

PMID:
30005774
28.

CSF-1/CSF-1R axis is associated with epithelial/mesenchymal hybrid phenotype in epithelial-like inflammatory breast cancer.

Kai K, Iwamoto T, Zhang D, Shen L, Takahashi Y, Rao A, Thompson A, Sen S, Ueno NT.

Sci Rep. 2018 Jun 21;8(1):9427. doi: 10.1038/s41598-018-27409-x.

29.

Impact of change in body mass index during neoadjuvant chemotherapy and survival among breast cancer subtypes.

Kogawa T, Fujii T, Fouad TM, Liu DD, Harano K, Masuda H, Iwase T, Barnett C, Park YS, Lim B, Tripathy D, Litton JK, Ueno NT.

Breast Cancer Res Treat. 2018 Sep;171(2):501-511. doi: 10.1007/s10549-018-4853-4. Epub 2018 Jun 18.

PMID:
29915946
30.

Safety and Efficacy of Panitumumab Plus Neoadjuvant Chemotherapy in Patients With Primary HER2-Negative Inflammatory Breast Cancer.

Matsuda N, Wang X, Lim B, Krishnamurthy S, Alvarez RH, Willey JS, Parker CA, Song J, Shen Y, Hu J, Wu W, Li N, Babiera GV, Murray JL, Arun BK, Brewster AM, Reuben JM, Stauder MC, Barnett CM, Woodward WA, Le-Petross HTC, Lucci A, DeSnyder SM, Tripathy D, Valero V, Ueno NT.

JAMA Oncol. 2018 Sep 1;4(9):1207-1213. doi: 10.1001/jamaoncol.2018.1436.

31.

Low-dimensional dynamical characterization of human performance of cancer patients using motion data.

Hasnain Z, Li M, Dorff T, Quinn D, Ueno NT, Yennu S, Kolatkar A, Shahabi C, Nocera L, Nieva J, Kuhn P, Newton PK.

Clin Biomech (Bristol, Avon). 2018 Jul;56:61-69. doi: 10.1016/j.clinbiomech.2018.05.007. Epub 2018 May 18.

PMID:
29803824
32.

Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay.

Gage MM, Mylander WC, Rosman M, Fujii T, Le Du F, Raghavendra A, Sinha AK, Espinosa Fernandez JR, James A, Ueno NT, Tafra L, Jackson RS.

Ann Oncol. 2018 May 1;29(5):1280-1285. doi: 10.1093/annonc/mdy074.

33.

Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies.

Eckhardt BL, Gagliardi M, Iles L, Evans K, Ivan C, Liu X, Liu CG, Souza G, Rao A, Meric-Bernstam F, Ueno NT, Bartholomeusz GA.

PLoS One. 2018 May 16;13(5):e0195932. doi: 10.1371/journal.pone.0195932. eCollection 2018.

34.

Author Correction: Inflammatory breast cancer biology: the tumour microenvironment is key.

Lim B, Woodward WA, Wang X, Reuben JM, Ueno NT.

Nat Rev Cancer. 2018 Aug;18(8):526. doi: 10.1038/s41568-018-0022-7.

PMID:
29748602
35.
36.

International Consensus on the Clinical Management of Inflammatory Breast Cancer from the Morgan Welch Inflammatory Breast Cancer Research Program 10th Anniversary Conference.

Ueno NT, Espinosa Fernandez JR, Cristofanilli M, Overmoyer B, Rea D, Berdichevski F, El-Shinawi M, Bellon J, Le-Petross HT, Lucci A, Babiera G, DeSnyder SM, Teshome M, Chang E, Lim B, Krishnamurthy S, Stauder MC, Parmar S, Mohamed MM, Alexander A, Valero V, Woodward WA.

J Cancer. 2018 Apr 6;9(8):1437-1447. doi: 10.7150/jca.23969. eCollection 2018.

37.

Survivorship and Advocacy in Inflammatory Breast Cancer.

Alexander A, Arnold TL, Bishnoi S, Ballinger C, Shaitelman SF, Schaverien MV, Cohen L, Dev M, Ueno NT.

J Cancer. 2018 Apr 6;9(8):1430-1436. doi: 10.7150/jca.21281. eCollection 2018.

38.

Inflammatory breast cancer biology: the tumour microenvironment is key.

Lim B, Woodward WA, Wang X, Reuben JM, Ueno NT.

Nat Rev Cancer. 2018 Aug;18(8):485-499. doi: 10.1038/s41568-018-0010-y. Review. Erratum in: Nat Rev Cancer. 2018 May 10;:.

PMID:
29703913
39.

Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer.

Ding Q, Wang Y, Zuo Z, Gong Y, Krishnamurthy S, Li CW, Lai YJ, Wei W, Wang J, Manyam GC, Diao L, Zhang X, Lin F, Symmans WF, Sun L, Liu CG, Liu X, Debeb BG, Ueno NT, Harano K, Alvarez RH, Wu Y, Cristofanilli M, Huo L.

Hum Pathol. 2018 Jul;77:121-129. doi: 10.1016/j.humpath.2018.04.002. Epub 2018 Apr 22.

PMID:
29689244
40.

Scientific Summary from the Morgan Welch MD Anderson Cancer Center Inflammatory Breast Cancer (IBC) Program 10th Anniversary Conference.

Woodward WA, Cristofanilli M, Merajver SD, Van Laere S, Pusztai L, Bertucci F, Berditchevski F, Polyak K, Overmoyer B, Devi GR, Sterneck E, Schneider R, Debeb BG, Wang X, van Golen KL, El-Zein R, Rahal OM, Alexander A, Reuben JM, Krishnamurthy S, Lucci A, Ueno NT.

J Cancer. 2017 Oct 9;8(17):3607-3614. doi: 10.7150/jca.21200. eCollection 2017.

41.

Development of CNS metastases and survival in patients with inflammatory breast cancer.

Uemura MI, French JT, Hess KR, Liu D, Raghav K, Hortobagyi GN, Arun BK, Valero V, Ueno NT, Alvarez RH, Woodward WA, Debeb BG, Moulder SL, Lim B, Tripathy D, Ibrahim NK.

Cancer. 2018 Jun 1;124(11):2299-2305. doi: 10.1002/cncr.31336. Epub 2018 Mar 26.

42.

The Emerging Impact of Social Media on Cancer Patient Education in Japan.

Sasaki Y, Ueno NT.

Oncologist. 2018 Sep;23(9):e105-e106. doi: 10.1634/theoncologist.2017-0670. Epub 2018 Mar 22. No abstract available.

43.

Dynamic changes in CD44v-positive cells after preoperative anti-HER2 therapy and its correlation with pathologic complete response in HER2-positive breast cancer.

Yamauchi T, Espinosa Fernandez JR, Imamura CK, Yamauchi H, Jinno H, Takahashi M, Kitagawa Y, Nakamura S, Lim B, Krishnamurthy S, Reuben JM, Liu D, Tripathy D, Chen H, Takebe N, Saya H, Ueno NT.

Oncotarget. 2018 Jan 4;9(6):6872-6882. doi: 10.18632/oncotarget.23914. eCollection 2018 Jan 23.

44.

Factors associated with improved outcomes for metastatic inflammatory breast cancer patients.

Weiss A, Menen RS, Lin HY, Shen Y, Rosso KJ, Shaitelman S, Woodward W, Valero V, Ueno NT, Bedrosian I, Babiera G.

Breast Cancer Res Treat. 2018 Jun;169(3):615-623. doi: 10.1007/s10549-018-4715-0. Epub 2018 Feb 19.

PMID:
29460033
45.

Expression of Programmed Death Ligand 1 (PD-L1) in Posttreatment Primary Inflammatory Breast Cancers and Clinical Implications.

He J, Huo L, Ma J, Zhao J, Bassett RL, Sun X, Ueno NT, Lim B, Gong Y.

Am J Clin Pathol. 2018 Feb 17;149(3):253-261. doi: 10.1093/ajcp/aqx162.

46.

Reply to Diagnosis of patients with inflammatory breast cancer is a problematic issue.

Arun BK, Gutierrez Barrera AM, Ueno NT.

Cancer. 2018 Feb 15;124(4):866. doi: 10.1002/cncr.31188. Epub 2017 Dec 19. No abstract available.

47.

Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer.

Fujii T, Matsuda N, Kono M, Harano K, Chen H, Luthra R, Roy-Chowdhuri S, Sahin AA, Wathoo C, Joon AY, Tripathy D, Meric-Bernstam F, Ueno NT.

Eur J Cancer. 2018 Jan;89:64-71. doi: 10.1016/j.ejca.2017.11.015. Epub 2017 Dec 9.

PMID:
29232568
48.

Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes.

Masuda H, Qi Y, Liu S, Hayashi N, Kogawa T, Hortobagyi GN, Tripathy D, Ueno NT.

Oncotarget. 2017 Jul 31;8(41):70481-70495. doi: 10.18632/oncotarget.19719. eCollection 2017 Sep 19.

49.

BRCA mutations in women with inflammatory breast cancer.

Gutierrez Barrera AM, Fouad TM, Song J, Webster R, Elsayegh N, Wood AL, Demir A, Litton JK, Ueno NT, Arun BK.

Cancer. 2018 Feb 1;124(3):466-474. doi: 10.1002/cncr.31069. Epub 2017 Oct 17.

50.

Association between weight gain during adjuvant chemotherapy for early-stage breast cancer and survival outcomes.

Schvartsman G, Gutierrez-Barrera AM, Song J, Ueno NT, Peterson SK, Arun B.

Cancer Med. 2017 Nov;6(11):2515-2522. doi: 10.1002/cam4.1207. Epub 2017 Oct 10.

Supplemental Content

Support Center